Browsing by Subject "GBS"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    COVID-19-Associated Bifacial Weakness with Paresthesia Subtype of Guillain-Barré Syndrome
    (American Society of Neuroradiology, 2020-06-25) Hutchins, Katherine L.; Jansen, Jaclyn H.; Comer, Adam D.; Scheer, Richard V.; Zahn, Gregory S.; Capps, Alisha E.; Weaver, Lindsay M.; Koontz, Nicholas A.; Neurology, School of Medicine
    We report a case of bifacial weakness with paresthesia, a recognized Guillain-Barré syndrome subtype characterized by rapidly progressive facial weakness and paresthesia without ataxia or other cranial neuropathies, which was temporally associated with antecedent coronavirus 2019 (COVID-19). This case highlights a potentially novel but critically important neurologic association of the COVID-19 disease process. Herein, we detail the clinicoradiologic work-up and diagnosis, clinical course, and multidisciplinary medical management of this patient with COVID-19. This case is illustrative of the increasingly recognized but potentially underreported neurologic manifestations of COVID-19, which must be considered and further investigated in this pandemic disease.
  • Thumbnail Image
    Item
    Environmental Toxicant Exposure Paralyzes Human Placental Macrophage Responses to Microbial Threat
    (American Chemical Society, 2023) Stephens, Victoria R.; Moore, Rebecca E.; Spicer, Sabrina K.; Talbert, Julie A.; Lu, Jacky; Chinni, Riya; Chambers, Schuyler A.; Townsend, Steven D.; Manning, Shannon D.; Rogers, Lisa M.; Aronoff, David M.; Vue, Zer; Neikirk, Kit; Hinton, Antentor O., Jr.; Damo, Steven M.; Noble, Kristen N.; Eastman, Alison J.; McCallister, Monique M.; Osteen, Kevin G.; Gaddy, Jennifer A.; Medicine, School of Medicine
    Exposure to environmental toxicants (such as dioxins) has been epidemiologically linked to adverse reproductive health outcomes, including placental inflammation and preterm birth. However, the molecular underpinnings that govern these outcomes in gravid reproductive tissues remain largely unclear. Placental macrophages (also known as Hofbauer cells) are crucial innate immune cells that defend the gravid reproductive tract and help promote maternal-fetal tolerance. We hypothesized that exposure to environmental toxicants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) could alter placental macrophage responses to inflammatory insults such as infection. To test this, placental macrophages were cultured in the presence or absence of TCDD and then infected with the perinatal pathogen Group B Streptococcus (GBS). Our results indicate that TCDD is lethal to placental macrophages at and above a 5 nM concentration and that sublethal dioxin exposure inhibits phagocytosis and cytokine production. Taken together, these results indicate that TCDD paralyzes placental macrophage responses to bacterial infection.
  • Thumbnail Image
    Item
    Multicenter Evaluation of NeuMoDx Group B Streptococcus Assay on the NeuMoDx 288 Molecular System
    (American Society for Microbiology, 2019-01-30) Emery, C. L.; Relich, R. F.; Davis, T. H.; Young, S. A.; Sims, M. D.; Boyanton, B. L.; Pathology & Laboratory Medicine, IU School of Medicine
    Group B Streptococcus (GBS) is the leading cause of neonatal sepsis and meningitis in developed countries. Recommendations for antepartum GBS detection include enriched culture with several options for identifying GBS, some of which are time-consuming. To reduce the time for identification and determination of the maternal GBS colonization status, rapid nucleic acid amplification technologies have been developed and commercialized. For rapid detection of GBS, a three-site clinical study was conducted to evaluate the NeuMoDx GBS assay, a real-time PCR test performed for vaginal/rectal swab specimens in Lim broth enrichment culture on the NeuMoDx 288 molecular system (NeuMoDx system); these data were used to a support 510(k) submission. A total of 1,250 eligible remnant samples were prospectively enrolled and tested during the study. The results of the PCR assay were compared to the results of the Centers for Disease Control and Prevention (CDC)-recommended enriched-culture method, which served as the gold standard reference method for the study. The NeuMoDx GBS assay results yielded a sensitivity of 96.9% (95% confidence interval [CI] = 94.1 to 98.4), specificity of 96.0% (95% CI = 94.6 to 97.1), and a total agreement with the reference method of 96.2% (95% CI = 93.8 to 98.3). NeuMoDx GBS assay results were also compared to results obtained using the BD MAX GBS assay on the BD MAX system. The two systems demonstrated a total percent agreement of 98.0% (95% CI = 95.5 to 100.0). The performance of the NeuMoDx GBS assay implemented on the NeuMoDx system compared favorably to the CDC enriched-culture method and to the BD MAX GBS assay.